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ABSTRACT
Objective: To describe early experience of replacing PSA with Stockholm3 for detection of pros-
tate cancer in primary care.
Design and methods: Longitudinal observations, comparing outcome measures before and
after the implementation of Stockholm3.
Setting: Stavanger region in Norway with about 370,000 inhabitants, 304 general practitioners
(GPs) in 97 primary care clinics, and one hospital.
Intervention: GPs were instructed to use Stockholm3 instead of PSA as standard procedure for
diagnosis of prostate cancer.
Main outcome measures: Proportion of GP clinics that had ordered a Stockholm3 test. Number
of men referred to needle biopsy. Distribution of clinically significant prostate cancer (csPC)
(Gleason Score 7) and clinically non-significant prostate cancer (cnsPC) (Gleason Score 6), in
needle biopsies. Estimation of direct healthcare costs.
Results: Stockholm3 was rapidly implemented as 91% (88/97) of the clinics started to use the
test within 14weeks. After including 4784 tested men, the percentage who would have been
referred for prostate needle biopsy was 29.0% (1387/4784) if based on PSA level 3ng/ml, and
20.8% (995/4784) if based on Stockholm3 Risk Score (p< 0.000001). The proportion of positive
biopsies with csPC increased from 42% (98/233) before to 65% (185/285) after the implementa-
tion. Correspondingly, the proportion of cnsPC decreased from 58% (135/233) before to 35%
(100/285) after the implementation (p< 0.0017). Direct healthcare costs were estimated to be
reduced by 23–28% per tested man.
Conclusion: Replacing PSA with Stockholm3 for early detection of prostate cancer in primary
care is feasible. Implementation of Stockholm3 resulted in reduced number of referrals for nee-
dle-biopsy and a higher proportion of clinically significant prostate cancer findings in performed
biopsies. Direct healthcare costs decreased.
KEY POINTS
A change from PSA to Stockholm3 for the diagnosis of prostate cancer in primary care in the
Stavanger region in Norway is described and assessed.
 Implementation of a new blood-based test for prostate cancer detection in primary care was
feasible. A majority of GP clinics started to use the test within three months.
 Implementation of the Stockholm3 test was followed by:
– a 28% reduction in number of men referred for urological prostate cancer work-up
– an increase in the proportion of clinically significant cancer in performed prostate biopsies
from 42 to 65%
– an estimated reduction in direct health care costs between 23 and 28%.
ARTICLE HISTORY
Received 11 November 2019








CONTACT Svein R. Kjosavik svein.kjosavik@sus.no The General Practice and Care Coordination Research Group, Stavanger University Hospital, P.O.
Box 8100, Stavanger, 4068, NorwayThe two first authors have contributed equally to this manuscript.
 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE
2020, VOL. 38, NO. 3, 315–322
https://doi.org/10.1080/02813432.2020.1802139
Introduction
Prostate cancer is the most common cancer diagnosis
in Norway, and the second leading cause of cancer-
related death in men. In 2017, the incidence and
prevalence were 4983 and 49,722, respectively, and
934 men died of prostate cancer [1]. Traditionally,
prostate-specific antigen (PSA) is used to identify men
at increased risk of prostate cancer, for follow-up of
men on active surveillance for low-risk prostate cancer,
and for control of men after treatment for prostate
cancer. For diagnostic purposes, current practice
includes using PSA. However, this is associated with
significant over-diagnosis and over-treatment of pros-
tate cancer as about two-third of patients are diag-
nosed with clinically non-significant prostate cancer
(cnsPC) defined as Gleason Score 6 [2,3]. Use of PSA is
also associated with under-diagnosis and under-treat-
ment of clinically significant prostate cancer (csPC)
defined as Gleason Score 7 in men with low PSA [4].
Additionally, there is a need for optimized risk-stratifi-
cation due to the risk of serious needle-biopsy-related
complications (e.g. sepsis) as the incidence of hospital-
ization due to severe infections is continuously
increasing [5].
Norwegian guidelines state that screening with PSA
testing is recommended only for men with genetic
predisposition [6]. Nevertheless, PSA testing is com-
mon. The number of conducted tests in 2011 corre-
sponded to 45% of men above 40 years of age, and a
large proportion of PSA testing of men is conducted
in primary care by general practitioners (GPs) [7].
Several recently developed blood-based tests have
proven superior properties compared to PSA for
selecting men for prostate biopsy [8–13]. The
Stockholm3 test has been developed at Karolinska
Institutet in Stockholm, Sweden, and predicts a man’s
risk of having a csPC in biopsy. Stockholm3 is a blood-
based test including analyses of PSA and four other
proteins, 101 genetic markers (single nucleotide poly-
morphisms) and clinical information (age, family his-
tory, earlier biopsies and use of 5-alpha reductase
inhibitors) [14,15]. The result of Stockholm3 includes a
recommendation for further follow-up, where men
with Stockholm3 Risk Score 11% are recommended
referral to urologist for further workup. A prospective
diagnostic study including 58,818 men showed that
Stockholm3 has substantially higher sensitivity and
specificity for clinically significant prostate cancer than
PSA [14]. The number of biopsies were reduced by 32
and 44% of the benign biopsies were avoided without
compromising the sensitivity to diagnose csPC [14].
Besides technical validation, the Stockholm3 test has
been externally validated in the STHLM3MRI project
on a cohort of 532 Norwegian and Swedish patients
already selected to perform a prostate needle-biopsy
by urologists based on current practice [16,17] and in
a clinical cohort of 573 men in Stockholm [18].
In 2016, after a thorough discussion involving GPs
and hospital doctors, Stavanger University Hospital
decided to start a project aiming to improve the diag-
nosis of prostate cancer. The project was launched in
2017. All GPs in the Stavanger region were recom-
mended to change from PSA to Stockholm3 as the
prostate cancer test for risk-stratification of men
before referral for further urological work-up. This
makes our county the first large healthcare region to
replace PSA with Stockholm3 for early detection of
prostate cancer in general practice.
This publication describes the early experiences of
implementing a novel diagnostic test in primary care
in a large healthcare region. It aims to (A) describe the
GPs response to the recommendation to replace PSA
with Stockholm3, (B) compare the results of replacing
PSA with Stockholm3 with regard to the percentage
of men being referred to biopsy, (C) compare the out-
come of needle-biopsies with regard to distribution of
csPC and ncsPC, and (D) estimate the impact on the
direct costs of prostate cancer diagnosis.
Design and methods
Setting and population
The Stavanger region is a geographical area, bounded
by the sea, fjords and mountains. The region has
370,000 inhabitants divided over 18 municipalities,
and 304 GPs in 97 clinics, three private urologists, and
one hospital. According to Statistics Norway, the num-
ber of men over the age of 40 in the region was
80,623 in 2017 and 81,953 in 2018.
Intervention
As of September 2017, all early detection of prostate
cancer in men in primary care in Stavanger region was
recommended by Stavanger University Hospital to be
done using Stockholm3 instead of PSA. GPs were
instructed to refer to urologist for further work-up if
the Stockholm3 Risk Score 11%, indicating an
increased risk of csPS.
The implementation of Stockholm3 started with a
meeting of the GPs at the Stavanger University hos-
pital in June 2017. In August 2017 all GPs received
written documentation about the new test, including
detailed instructions and necessary laboratory
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equipment. GPs were advised to continue their diag-
nostic practice as before, but to use Stockholm3
instead of PSA when they decided to test patients
without known prostate cancer. The start-up of the
new routine was set to September 2017, and GPs
were informed that after September 18th, referrals to
the hospital based on PSA could be rejected because
the hospital wanted to use Stockholm3 for prioritiza-
tion of patients.
Since the research aims to analyse the consequen-
ces of the change from PSA to Stockholm3 in clinical
practice, without affecting the demand for testing, a
strategy to avoid media attention was developed in
collaboration with the Norwegian Cancer Society and
the Norwegian Prostate Cancer Association. Thus,
information about the ongoing research was pub-
lished in the general media only after the inclusion of
patients in the study had ended.
The project was approved by the Regional
Committee for Medical Research Ethics (2017/71 REK
Vest) in March 2017.
Method
During the implementation process, the conversion
rate from PSA to Stockholm3 among the GPs was
monitored. Based on the real-life outcome data from
4784 men tested (from September 1st 2017 to
October 12th 2018), we compared PSA values with
Stockholm3 recommendation for needle-biopsy. A cut-
off for PSA 3ng/ml was chosen as a positive PSA test
in our analysis because the Stockholm3 test was
developed with a cut-off for a positive test corre-
sponding to the risk of a csPC at PSA ¼ 3ng/ml. In
addition, this level has been used in other papers
regarding the Stockholm3 test [13,14,16], and accord-
ingly, this provides an appropriate basis for
comparison.
At the department of pathology, all positive biopsy
outcomes are routinely sent for registration at the
Norwegian Cancer registry. These records were
retrieved for the periods January to June 2017 (before
the implementation of Stockholm3) and for January to
June 2018 (after the implementation of Stockholm3).
In cases where there was more than one report on
the same patient, the report with the highest Gleason
score was included in the analysis (i.e. 8 reports from
2017 and 8 reports from 2018 were excluded because
the same patient was biopsied twice). Information
regarding negative biopsies were not included in the
analysis as negative (non-neoplastic) biopsies are not
reported to the cancer registry.
Statistical analysis
The data were analysed with descriptive statistical
methods, as percentages, proportions and rates.
Differences in rates were tested with chi-square tests.
Results are shown with confidence intervals and p-val-
ues. The proportion of csPC was calculated as number
of csPC divided by total number of positive biopsies.
Based on cost estimates from Stavanger University
Hospital combined with outcome data from 4784 men
tested with Stockholm3, a simplified health economy
cost-model for replacing PSA with Stockholm3 for
diagnosis of prostate cancer in men was calculated.
Costs were calculated as: Total costs¼Cost blood
samplingþ cost blood analysis PSAþ cost blood ana-
lysis Stockholm3þ cost trans-rectal ultrasound (TRUS)
þ cost magnetic resonance imaging (MRI; including
MRI protocol and radiologist) þ costs needle-biopsy
and pathology workupþ cost sepsis following needle-
biopsy. Regarding costs based on PSA, separate
assessment was made using a re-biopsy rate of 30%
and 60%, and a post-biopsy sepsis rate of 2 and 5%. A
p-value <0.05 was considered statistically significant.
OpenEpi (version3.01: Dean AG, Sullivan KM, Soe
MM) was used to compare rates, and confidence inter-
vals and p-values were calculated using their recom-
mended methods.
Results
Regarding the implementation of Stockholm3
In the study period, 5005 Stockholm3 tests were con-
ducted, of which 221 tests were excluded due to lack
of documented patient consent, missing information
or other errors. Thus, 4784 men underwent
Stockholm3 testing and were included in the study.
Fourteen weeks after initiation date 88 of 97 (91%)
of the GP clinics in the region had at least one man
conducted a Stockholm3 test, and after 12months,
only 3 of 97 (3%) GP clinics had not used the test.
(Figure 1).
The test rate increased during the first three
months and reached a peak of 148 tests in one week,
twelve weeks after start-up. The test rate thereafter
declined, showing a negative linear test trend. During
national holidays (Christmas, Easter, the summer holi-
day), fewer men were tested (Figure 1). During the
first 12months, the mean number of Stockholm3
referrals per GP was 16, corresponding to about one
test every 25th day.
PSA usage in the Stavanger region increased on
average by 433 tests a year from 25,218 tests in 2010
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to 27,815 tests in 2016 (before the implementation). If
this trend had continued, it would have resulted in
28,249 tests in 2017 and 28,682 tests in 2018. The
actual figures of PSA and Stockholm3 tests together
were 27,886 in 2017 and 27,975 in 2018 (after the
implementation). Accordingly, the annual increase in
test activity has been reduced after the implementa-
tion of the Stockholm3 test.
Regarding Stockholm3 compared to PSA
Of the men included in the study, 995/4784
(20.8%) had a positive Stockholm3 Risk Score
(Stockholm3 Risk Score 11%), while 1387 (29.0%)
had positive PSA (PSA 3.0 ng/ml) (Table 1). The
proportion of cases where further referral was indi-
cated thus differed 8 percentage points, correspond-
ing to a 28% relative decrease in number of tested
men who would be referred for further workup.
In addition, 520/4784 (11%) had positive PSA
and negative Stockholm3, and 128/4784 (3%) had
negative PSA but positive Stockholm3 test. To
mimimize unnecessary testing, men who had a
Stockholm3 risk score 3%, 49.3% (n¼ 2358) were
recommended a prolonged interval to subsequent
testing [19].
Figure 1. Number of Stockholm3 samples, and number of GP offices that had started to use Stockholm3, per week during the
first year after initiation.
Table 1. Distribution of 4784 Stockholm3 tests with risk score and recommendations, compared
with corresponding results when based on PSA.
Note: Test results indicating a referral for further urological work-up is encircled.
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Regarding needle-biopsy outcome
In total, 518 needle-biopsy reports from the depart-
ment of pathology regarding the diagnosed patients
with prostate cancer were included in the analysis.
Table 2 shows the distribution by year, age groups
and Gleason score.
The number of csPC increased from 98 before to
185 after the implementation of the Stockholm3 test.
In the same time period, the number of cnsPC
decreased from 135 to 100. These changes are statis-
tically significant, also when adjusted for the slight
change in the age distribution. The proportion of
biopsies positive for cancer that showed csPC
increased from 42.1% (98/223) before implementation
to 64.9% (185/285) after implementation of
Stockholm3 in the Stavanger region. Correspondingly,
both the number and the rate of cnsCP decreased
from 135/57.9% before implementation to 100/35.1%
after implementation of Stockholm3.
Regarding direct costs
Using cost estimates from the Stavanger region and
outcome of the study population (n¼ 4784), we calcu-
lated the impact on the direct costs of using PSA ver-
sus Stockholm3 in our study population.
According to a review [20], the percentage of nega-
tive result in first prostate biopsies when based on
PSA is up to 70%. According to the European
Association of Urology [21] (and also the Norwegian
guidelines [6]), these patients are often recommended
to be re-biopsied. We have not found documentation
about level of re-biopsies in the literature, but from a
population-based registry from the Stockholm region
about 35% of patients biopsied on the basis of a PSA
test were re-biopsied (Unpublished data, personal
communication Tobias Nordstr€om). In this assessment,
we have estimated the direct costs if 35% of cases are
re-biopsied when biopsies are based on PSA. When
the biopsies are based on Stockholm3, we have used
the registered number of re-biopsies in this study.
One main effect of introducing Stockholm3 is a
reduced need for biopsies. The cost of treating post-
biopsy sepsis has therefore been included as a rele-
vant cost saving directly related to the intervention.
The risk of sepsis after transrectal prostate biopsy is
stated to be 2–5% [22]. It is therefore included in the
calculation what the costs will be if 2 or 5% of the
cases got sepsis. As shown in Figure 2, the average
expected cost to test one man for prostate cancer is
between 6046 and 7238 Norwegian kroner using PSA
3 ng/ml, and between 4632 and 5217 Norwegian
kroner using Stockholm3 Risk Score 11% as cut-off
for referring a man to urologist. This corresponds to a
decrease in direct healthcare costs per man tested
using Stockholm3 instead of PSA of between 23 and
28% (Figure 2).
Discussion
This study illustrates several points related to imple-
menting a new prostate cancer diagnostic test in pri-
mary care. First, more than 90% of the GP clinics
started to use the new test within 14weeks of intro-
ducing the new procedure. On average, the GPs in the
Table 2. The number and rate of positive biopsies in 2017 before the intervention (using PSA) and in 2018 after the implemen-
tation of Stockholm3, by age group and Gleason score; related to the population, and the figures for 2018 when standardizing
the results regarding the population changes.
2017 (Before implementation) 2018 (After implementation of Stockholm3)
Age group Population N Rate/10,000 Person years CI Population N
Rate/10,000
Person years CI p
Gleason 6
40–49 26546 2 1.5 0.3–5.0 26323 2 1.5 0.3–5.0 0.99
50–59 22599 29 25.7 17.5–36.4 23058 22 19.1 12.3–28.4 0.30
60–69 17165 68 79.2 62.0–99.8 17543 50 57.0 42.8–74.6 0.08
70–79 9796 36 73.5 52.3–100.1 10437 24 46.0 30.2–67.4 0.07
80 þ 4517 0 4592 2 8.7 1.5–28.8 0.25
Sum 80623 135 33.5 28.2–39.5 81953 100 24.4 20.0–29.6 0.016
Standardized to 2017 age-distribution 24.8 20.3–30.0 0.023
Gleason 7
40–49 26546 0 26323 2 1.5 0.3–5.0 0.25
50–59 22599 10 8.9 4.5–15.8 23058 22 19.1 12.3–28.4 0.04
60–69 17165 34 39.6 27.9–54.7 17543 67 76.4 59.7–96.4 0.001
70–79 9796 46 93.9 69.6–124.2 10437 80 153.3 122.4–189.8 0.007
80 þ 4517 8 35.4 16.5–67.3 4592 14 61.0 34.7–99.9 0.22
Sum 80623 98 24.3 19.8–29.5 81953 185 45.2 39.0–52.0 <0.000001
Standardised to 2017 age-distribution 45.9 39.6–52.9 <0.000001
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region requested the new prostate cancer test every
25th day during the study period. Secondly, using the
new test instead of the traditionally used PSA, needle-
biopsy referral could be reduced by 28%. Thirdly, in
men undergoing biopsies, the proportion with csPC
increased during the period. This indicates increased
sensitivity for csPC and decreased risk of over-diagno-
sis. Lastly, a health-economic cost estimate showed
lower costs using the new test due to lower costs for
MRI, biopsies and sepsis.
One reason for the rapid implementation of the
Stockholm3 might be that the GP’s were not satisfied
with the use of PSA and the uncertainty regarding the
interpretation of the results. Dealing with uncertainty
and patients’ expectations is challenging for the GPs
[7]. A Stockholm3 result includes a recommendation
and not just a number. The promise of a better diag-
nostic test with clear guidelines is a powerful incentive
for change.
As in other parts in Scandinavia, prostate cancer
testing in Stavanger is common [23]. Considering the
rapid implementation of the new test, it was
reassuring that the annual increase in test activity in
the period 2010 to 2016 was less after the implemen-
tation of Stockholm3. After the initial increase in use
of Stockholm3, it appeared that the test rate declined
to a new ‘steady state’ after about a year. The trend in
using the test also confirms that the project managed
to keep the information about the research with
Stockholm3 away from the media, thus avoiding an
increase in general public demand for the new test.
The 4784 Stockholm3 tests conducted during the
study generated 995 biopsy recommendations. This
should be compared to the 1387 biopsy recommenda-
tions resulting from using PSA 3 ng/ml as the decid-
ing test. This 28% reduction in biopsy
recommendations is significant not only for the men
(who do not have to undergo a procedure that is
laborious and potentially dangerous) but also because
it frees up scarce healthcare resources in departments
of urology, radiology and pathology.
It may be argued that many GPs do not necessarily
refer patients with a PSA of 3 ng/ml to specialists.
Instead, they may use age-related cut-off values for
Figure 2. Number and costs for 4784 men, in total and per tested man, with Stockholm3 compared with estimated cost if the
diagnosis would have been based on PSA.
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PSA or follow the changes in PSA over time before
deciding to refer a man for further diagnosis. It is a
limitation of this paper that no more detailed analysis
has been made of the effect of the change from PSA
to Stockholm3 for different age groups or with differ-
ent cut-off values for PSA. PSA is used not only for the
diagnosis of prostate cancer, but also for active sur-
veillance of patients with low-risk prostate cancer and
for the follow-up of patients being treated for prostate
cancer, and it was not possible in this study to distin-
guish the tests taken for diagnostic purposes from the
others. However, if the diagnosis of prostate cancer
has previously been based on a higher PSA value, the
increase in the proportion of diagnosed csPC after the
implementation of the Stockholm3 test is underesti-
mated in our analysis.
The direct cost calculation shows that introducing
new, improved diagnostics in primary care does not
necessary increase overall healthcare costs. Instead,
the direct costs for healthcare is reduced by between
23 and 28%, because Stockholm3 reduces the num-
bers of MRIs, biopsies and sepsis treatment needed
compared to use of PSA. It might be worth noting
that the actual cost of the Stockholm3 test itself is
higher than PSA, but introducing better tools for the
GP may still reduce the overall costs for the healthcare
system. It should also be noted that this study has not
conducted a complete cost efficiency study including
burden of disease impact or external costs.
There are several suggestions for novel prostate
cancer tests, including 4 K Score, phi, and the
Stockholm3 test [8,14]. All these tests have been
shown to outperform PSA or combination of clinical
information. Based on existing evidence including val-
idation in a Scandinavian population, Stavanger
Region chose to use Stockholm3 for primary prostate
cancer diagnostics. Our results are in agreement with
the conclusions from Capio S:t G€oran Prostate Cancer
Centre in Stockholm, Sweden [18] and the health
authorities in Stockholm who have decided to imple-
ment the Stockholm3 test in their region [23]. It
should however be noted that PSA still represents an
important tool for follow-up after treatment for pros-
tate cancer.
It is a weakness of the study that information about
negative biopsies is not included in the analysis, but
these figures will not affect the proportion of cnsPC
versus csPC. The results of pre-biopsy MRIs is not
included either, but pre-biopsy MRI have been done
routinely in the region since 2013. As MRI routines
have not changed during the study period, we do not
attribute the change in proportion of cnsPC versus
csPC to MRI. Nevertheless, the prostate cancer diag-
nostic process is complex and undergoing continuous
development. Thus, we cannot exclude other diagnos-
tic interventions that may have performed differently
over the course of the study period, possibly affecting
the differences in biopsy outcome reported here.
Furthermore, PSA may still have been used during the
study period, possibly diluting any measured effects
related to the Stockholm3 test. Lastly, despite the iso-
lated nature of the study site (Stavanger Region), we
cannot exclude a limited number of men in Stavanger
that had a prostate cancer test outside Stavanger.
Likewise, men from outside the region may have
sought testing and treatment in Stavanger.
Conclusions
Replacement of PSA with Stockholm3 in primary care
in the Stavanger region was feasible. Most GP clinics
started using the test within three months. The need
for biopsies decreased significantly while the propor-
tion of clinically significant prostate cancer in per-
formed biopsies increased considerably after the
implementation of Stockholm3. In addition, direct
healthcare costs were reduced.
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